Delivery Order SPE2DB22D1017-SPE2DB25FG8EE
- Not listed
- The Defense Logistics Agency awarded a $51,202.00 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 17, 2025, with an ultimate completion date of July 18, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $32,555.23 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 26, 2025, with an ultimate completion date of August 27, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $4,684.70 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 4, 2025, with completion scheduled for June 5, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating open competitive award. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and this delivery...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $14,136.53 for RINVOQ ER 15 mg tablets (30-count units) on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $21,375.83 for RINVOQ ER 15 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract is non-set-aside and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $7,250.75 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 21, 2025, with completion scheduled for August 22, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform...
- The Defense Logistics Agency awarded a $15,876.35 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed price contract, with an ultimate completion date of July 21, 2025, represents a non-competitive delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,789.62 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The order is scheduled for completion by July 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $8,191.05 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 14, 2025, with an ultimate completion date of July 15, 2025. This firm fixed price, competitively awarded delivery order represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with the federal government. The contract is not set aside and will be performed at the vendor's corporate office location in...
- The Defense Logistics Agency awarded a $3,111.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count) on July 14, 2025, with completion due July 15, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG8EEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $10,772.76 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on July 25, 2025, with completion expected by July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a procurement of pharmaceutical inventory supporting military healthcare operations. The contract carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceuticals and medical supplies to military healthcare systems worldwide. AmerisourceBergen's status as a major pharmaceutical distributor and critical federal vendor is demonstrated through its extensive portfolio of medical product deliveries, with contracts ranging from small-value transactions to substantial orders exceeding $45,000, serving customers including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.8k | 7/25/25 |